ABHI 2017: Hopes, Fears And Opportunities On UK Medtech Agenda
Securing market access at a time of an unprecedented budget squeeze, driving forward with medtech and digital innovation plans and maintaining barrier-free access to the EU market: these are the uppermost thoughts on the minds of UK medtech bosses. It's hard, but it's not mission impossible, industry and government leaders said at the ABHI's 2017 UK Market Conference.
You may also be interested in...
More and more details are emerging about the likely impact of Brexit, as MedTech Europe shows in its newly publicized position paper. Will some companies even come to regret hiring UK notified bodies?
The UK devices and diagnostics industries were quick to react to the long-overdue government response to the fall 2016 Accelerated Access Review, a proposal to fast-track innovation into the NHS to the benefit of UK science, patients and the economy. Coinciding with Brexit, it is a fine-sounding plan, but will there be practical follow-through for medtech too?
The UK National Institute for Health and Care Excellence is working on a new database of pre-launch-phase medtech products. The aim is to give NHS providers enough time to plan for the uptake of innovative technologies and, generally, to improve the pathway between development and adoption, says NICE medtech programs director Mirella Marlow.